Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'Inflaming tensions': Bedouin mayor slams Ben-Gvir's unauthorized visit after meeting cancellation - 2I’m a neuroscientist who taught rats to drive − their joy suggests how anticipating fun can enrich human life
- 3Former 'Bachelorette' welcomes 1st baby via emergency c-section
- 4Jasmine Crockett in, Colin Allred out: A major shakeup for Democrats in their quest to finally win a Senate seat in Texas
- 5Ten Awesome Authentic Realities That Will Leave You Interested
- 2025 Was Another Exceptionally Hot Year
- Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds
- 6 Hints to Upgrade Your Appeal, In addition to Your Outlook
- Flights canceled at 40 U.S. airports: Follow live updates as FAA cuts to air traffic take effect amid government shutdown
- 6 Travel Services for Colorful Get-aways: Pick Your Fantasy Escape
- What loving-kindness meditation is and how to practice it in the new year
- Marvel's X-Men are joining the battle in 'Avengers: Doomsday': Watch the teaser
- Inside The Design-Forward Wellness Hotel Marking A New Chapter In Medellín
- April’s full pink moon will rise in the night sky this week
